|
|
|
|
Randomized Studies of Once-Daily Darunavir and of Tenofovir/FTC + Nevirapine
Save time and stay informed.Our physician-editors offer you clinical perspectives on key research and news. Data presented at the 2010 Retrovirus Conference highlighted the potential for darunavir to be dosed once daily in treatment-experienced patients...
|
|
|
Detection of HIV-1-Drug-Resistance in Women Following Single-Dose-Nevirapine: Comparison of Plasma RNA versus Cellular DNA by Consensus Sequencing and by Oligonucleotide Ligation Assay
Wagner TA et al.Detection of HIV-1-Drug-Resistance in Women Following Single-Dose-Nevirapine: Comparison of Plasma RNA versus Cellular DNA by Consensus Sequencing and by Oligonucleotide Ligation Assay.
|
|
|
Nevirapine Can Be Resumed 1 Year After Childbirth in Mothers With HIV
my personal edition> aids and hiv > news E-Mail this DGNews to a colleague DGNews BIRMINGHAM, Ala -- March 2, 2010 -- Women with HIV who are given nevirapine to protect their fetus should not use an HIV-drug regimen that contains nevirapine for at...
|
|
|
HIV drug given to protect a foetus should be avoided for one year after childbirth
Women given the human immunodeficiency virus (HIV) prevention drug nevirapine to protect their foetus should not use an HIV-drug regimen that contains nevirapine for at least one year after childbirth, say researchers at the (UAB).A new UAB study found that...
|
|
|
HIV drug that protects a fetus should be avoided for one year after childbirth, researchers say
Women given the (HIV) prevention drug nevirapine to protect their fetus should not use an HIV-drug regimen that contains nevirapine for at least one year after childbirth, say researchers at the University of Alabama at Birmingham (UAB).A new UAB study found...
|
|
|
HIV Drug Given to Protect a Fetus Should Be Avoided for One Year After Childbirth
Women given the human immunodeficiency virus (HIV) prevention drug nevirapine to protect their fetus should not use an HIV-drug regimen that contains nevirapine for at least one year after childbirth, say researchers at the University of Alabama at Birmingham ...
|
|
|
HIV drug that protects a fetus should be avoided for one year after childbirth, researchers say
Women given the human immunodeficiency virus (HIV) prevention drug nevirapine to protect their fetus should not use an HIV-drug regimen that contains nevirapine for at least one year after childbirth, say researchers at the University of Alabama at Birmingham ...
|
|
|
Aurobindo Pharma Receives Tentative Approval For Nevirapine
Aurobindo Pharma has received tentative approval to manufacture and market Nevirapine tablets for oral suspension 50mg from the FDA.The new drug application 22-299 provides for the use of Nevirapine tablets for oral suspension 50mg in combination...
|
|
|
Aurobindo Pharma receives tentative approval for Nevirapine tablets
Aurobindo Pharma announced that it has received a tentative approval to manufacture and market Nevirapine tablets for oral suspension 50 mg New Drug Application (NDA) from the US Food & Drug Administration (USFDA).Aurobindo Pharma receives...
|
|
|
HIV drug that protects a fetus should be avoided for one year after childbirth, researchers say
BIRMINGHAM, Ala.Women given the human immunodeficiency virus (HIV) prevention drug nevirapine to protect their fetus should not use an HIV-drug regimen that contains nevirapine for at least one year after childbirth, say researchers at the (UAB). A new UAB...
|
|
|
Aurobindo Gets FDA Nod for HIV Drug
Hyderabad-based pharmaceutical company Aurobindo Pharma announced Thursday that it has received the tentative approval to manufacture and market Nevirapine tabl Aurobindo Gets FDA Nod for HIV Drug.
|
|
|
HIV Drug Given To Protect A Fetus Should Be Avoided For One Year After Childbirth
Women given the human immunodeficiency virus (HIV) prevention drug nevirapine to protect their fetus should not use an HIV-drug regimen that contains nevirapine for at least one year after childbirth, say researchers at the University of Alabama at Birmingham ...
|
|
|
Aurobindo Pharma gets FDA approval for HIV treatment
Aurobindo Pharma, a Hyderabad, India-based midtier pharma company has received the tentative approval to manufacture and market Nevirapine Tablets for Oral Sus Aurobindo Pharma gets FDA approval for HIV treatment.
|
|
|
Nevirapine taken to protect fetus from HIV should be avoided for one year after childbirth, say researchers
Affordable health care can save millions of women, newborns, and children in sub-Saharan AfricaThe lives of almost 4 million women, newborns, and children in sub-Saharan Africa could be saved eve...Patients increasingly charged 'facility fees'Kaiser Health News...
|
|
|
HIV Drug Given to Protect a Fetus Should be Avoided for One Year After Childbirth
Newswise - Women given the human immunodeficiency virus (HIV) prevention drug nevirapine to protect their fetus should not use an HIV-drug regimen that contains nevirapine for at least one year after childbirth, say researchers at the University of Alabama at...
|
|
|
HIV Drug Given to Protect a Fetus Should be Avoided for One Year After Childbirth
Source: University of Alabama at Birmingham Newswise Women given the human immunodeficiency virus (HIV) prevention drug nevirapine to protect their fetus should not use an HIV-drug regimen that contains nevirapine for at least one year after childbirth, say...
|
|
|
HIV Drug Resistance Lasts for 1 Year in Women Given Nevirapine to Prevent Infant Infection
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
|
|
HIV Drug Resistance Lasts for 1 Year in Women Given Nevirapine to Prevent Infant Infection
_ HIV Drug Resistance Lasts for 1 Year in Women Given Nevirapine to Prevent Infant Infection.
|
|
|
HIV Drug Resistance Lasts for 1 Year in Women Given Nevirapine to Prevent Infant Infection
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
|
|
HIV Drug Resistance Lasts for 1 Year in Women Given Nevirapine to Prevent Infant Infection
_ HIV Drug Resistance Lasts for 1 Year in Women Given Nevirapine to Prevent Infant Infection.
|
|
|
Nevirapine Therapy: Studies from Boehringer Ingelheim GmbH in the area of nevirapine therapy described
Today's Medical & Research News Nevirapine Therapy Studies from Boehringer Ingelheim GmbH in the area of nevirapine therapy described February 23rd, 2010 Printer-Friendly Version City:Ridgefield State:CT Country:United States Biopharmaceuticals Drugs ...
|
|
|
Studies from Boehringer Ingelheim GmbH in the area of nevirapine therapy described
'An in vitro-in vivo correlation (IVIVC) for four nevirapine extended release tablets with varying polymer contents was developed.The pharmacokinetics of extended release formulations were assessed in a parallel group study with healthy volunteers and...
|
|
|
Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095
Schouten JT et al.In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy. Substitution...
|
|
|
CROI: Nevirapine Survives Second Test
Nevirapine Survives Second Test - in , from MedPage Today NEW CME/CE TRACKER Personalize Your Medical News: CME Information Jointly Sponsored by: and MedPage Today CREDITS Physicians: 0.25 AMA PRA Category 1 Credit(s) Family Physicians: 0.25 Elective...
|
|
|
In Women Treated With Nevirapine to Prevent Infant Infection, HIV Drug Resistance Lasts for 1 Year
A single dose of nevirapine (sdNVP) can lead to HIV treatment failure in women who receive the drug to prevent transmission of the AIDS virus to their infants, a new international study reported in PLoS Medicine has confirmed.However, the increased risk of...
|
